AMICUS AI
Citation Codes
Equivalent Citations
citation codes
Docket Number
Attorney(S)
Judges
Are you a practicing lawyer?
Enhance your digital presence and reach by creating a Casemine profile.
Upload pleading to use the new AI search
Cites
Cited by
Citation Codes
Equivalent Citations
citation codes
Docket Number
Attorney(S)
Judges

MELISSA JONES, AN INFANT UNDER THE AGE OF 14 YEARS, BY HER FATHER AND NATURAL GUARDIAN, RICHARD JONES, PLAINTIFF-APPELLANT, v. LEDERLE LABORATORIES, A DIVISION OF AMERICAN CYANAMID CO., DEFENDANT-APPELLEE.

PER CURIAM:

Melissa Jones appeals from the March 30, 1992, judgment of the District Court for the Eastern District of New York (Jack B. Weinstein, Judge), granting judgment for defendant Lederle Laboratories under Fed. R.Civ.P. 50(b) after a jury returned a verdict in her favor. Jones, a severely retarded thirteen-year-old girl, alleged in a diversity suit that she suffered adverse side effects from the pertussis component of a DTP vaccine manufactured by Lederle, which was administered to her in 1979. At the trial the issue principally contested was whether the "whole cell" pertussis vaccine used by Lederle was unreasonably unsafe, despite its acknowledged benefits, because of the alleged ability of Lederle to develop and manufacture an alternative "acellular" form of pertussis vaccine that would have produced less risk of adverse side effects.

Judge Weinstein ruled that the evidence was insufficient to permit the jury to conclude that "by 1979, the defendant could have developed, produced and proven to the FDA's satisfaction the efficacy and safety of an acellular vaccine for use on Melissa Jones." Jones v. Lederle Laboratories, 785 F.Supp. 1123, 1127 (E.D.N.Y. 1992). We affirm on Judge Weinstein's opinion.

Use AI to get other relevant cases.

Comments

JONES v. LEDERLE LABORATORIES
(Dec 21, 1992)